Halozyme Therapeutics (NASDAQ:HALO) Stock Unloaded by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Halozyme Therapeutics stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Halozyme Therapeutics Trading Down 1.3%

Shares of HALO stock opened at $109.62 on Wednesday. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $116.85. The company has a market cap of $12.44 billion, a PE ratio of 32.72, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business’s 50 day moving average is $107.30 and its two-hundred day moving average is $83.87.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently made changes to their positions in the stock. CoreCap Advisors LLC grew its holdings in Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 150 shares during the period. Twin Capital Management Inc. raised its stake in shares of Halozyme Therapeutics by 1.4% in the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 161 shares during the period. First Citizens Bank & Trust Co. raised its stake in shares of Halozyme Therapeutics by 2.0% in the first quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 175 shares during the period. Nations Financial Group Inc. IA ADV raised its stake in shares of Halozyme Therapeutics by 1.2% in the first quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock valued at $981,000 after buying an additional 183 shares during the period. Finally, Janney Montgomery Scott LLC lifted its position in shares of Halozyme Therapeutics by 0.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,373 shares of the biopharmaceutical company’s stock valued at $1,640,000 after buying an additional 202 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, Director Matthew Posard sold 18,996 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the transaction, the director owned 58,839 shares in the company, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on HALO shares. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. TD Cowen increased their price objective on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $96.50.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.